Elon Musk Teases Tesla Merger and $1 Trillion Milestone for SpaceX
Elon Musk stated SpaceX could achieve $500 billion to $1 trillion in annual recurring revenue by 2027, with the upper end contingent on expanding compute capacity. He also mentioned potential merger talks between SpaceX and Tesla, requiring 50% shareholder approval. SpaceX's Q3 revenue was $14.6 billion, up 161% YoY, with net income at $4.4 billion. Super Intelligence revenue grew 830%, driven by Starlink. Musk is not involved in merger discussions.
How this was made

The 30-second read
Why it matters
The remarks introduce new merger speculation, which could drive short‑term volatility in TSLA and related tech stocks.
Market read
Fresh merger speculation may prompt traders to position ahead of any formal announcement, but the lack of concrete terms limits actionable decisions.
What to watch
Regulatory scrutiny, antitrust concerns, and financing constraints could impede any deal.
Background
Elon Musk discussed SpaceX's ARR targets and hinted at a possible Tesla‑SpaceX combination during SpaceX's Q3 webcast.
Ticker impact
Elon Musk said special committees at Tesla are exploring a possible merger with SpaceX, requiring at least 50% shareholder approval.
potential upside pressure as investors price in merger possibilities, but also downside risk if talks stall.
The comment is a fresh primary quote about a potential deal; no terms are set, so market reaction will be speculative.
Market effects
Potential merger could reshape the automotive and space sectors, influencing EV and satellite competitors.
U.S. markets may see heightened activity in technology and aerospace stocks.
Global investors may watch the story for broader implications on high‑growth tech conglomerates.
Counterpoint
The merger talk may be a distraction; without concrete terms, the risk of a false rally is high.
Key entities
- personElon Musk
CEO of Tesla and founder of SpaceX, source of the merger speculation.
- companyTesla
Electric vehicle maker potentially involved in a merger with SpaceX.


